MedTrace Logo

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

NCT04079530 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-06

No results posted yet for this study

Summary

A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.

Conditions

  • Dyslipidemias

Interventions

DRUG

K-877 IR 0.2 mg/day

K-877 IR 0.1 mg tablet

DRUG

K-877 CR 0.4 mg/day

K-877 CR 0.4 mg tablet

DRUG

K-877 CR 0.8 mg/day

Two K-877 CR 0.4 mg tablet

Sponsors & Collaborators

  • Kowa Company, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-13
Primary Completion
2019-12-24
Completion
2019-12-24

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04079530 on ClinicalTrials.gov